Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry☆

Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry☆

Background: Predictive biomarkers guide treatment selection of patients with advanced gastric and gastroesophageal junction adenocarcinoma (GAC/GEJAC). However, real-world data on testing frequencies and prevalence of biomarkers in Europe are limited. Methods: The SAPHIR registry, a prospective, obs...

Full description

Saved in:
Bibliographic Details
Main Authors: K. Potthoff, H. Bläker, T. Dechow, A. Binninger, K. Ringwald, R. de Buhr, E. von der Heyde, M.-O. Zahn, A. Nusch, S. Dörfel, H. Schulz, I. Haffner, A.K. Höhn, A. Monecke, S. Lorenzen, A. Reinacher-Schick, M. Jänicke, F. Lordick
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
biomarker
gastric cancer
HER2
PD-L1
real-world data
test deviation
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820125000335
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items